Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Trastuzumab Deruxtecan in HER2-Altered Solid Tumors
NCT05372614Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2022
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neratinib and trastuzumab deruxtecan in solid tumor and pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities, Treatment-Emergent Adverse Events and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
neratinibtrastuzumab deruxtecan
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05372614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372614.